GD and CD produced similar efficacy and toxicity profiles consistent with prior clinical experience.

The purpose of this study is to evaluate the frequency of viral and bacterial respiratory pathogens detected by molecular methods in sputum samples of patients hospitalized for COVID-19 and to evaluate its impact on mortality and unfavorable outcomes (inhospital death or mechanical ventilation). Patients and Methods: The prospective cohort included patients with diagnosis of COVID-19 hospitalized at Hospital Nacional Hipólito Unanue. Sociodemographic and clinical data were collected from clinical records. Sputum samples were analyzed with the Biofire Filmarray Pneumonia plus ® respiratory panel. Crude and adjusted associations with unfavorable outcomes were evaluated using logistic regression models. Results: Ninety-three patients who were able to collect sputum samples were recruited between September 8 and December 28, 2020. The median age was 61.7 years (IQR 52.3-69-8) and 66 (71%) were male. The most frequent symptoms were dyspnea, cough, fever, and general malaise found in 80 (86%), 76 (82%), 45 (48%), and 34 (37%) patients, respectively. Fifty-three percent of patients had comorbidities. Seventy-six (82%) patients received antibiotics prior to admission and 29 (31%) developed unfavorable outcome. Coinfection was evidenced in 38 (40.86%) cases. The most frequently found bacteria were Staphylococcus aureus, Streptococcus agalactiae, Haemophilus influenzae and Klebsiella pneumoniae in 11 (11.83%), 10 (10.75%), 10 (10.75%), and 8 (8.6%) cases, respectively. Streptococcus pneumoniae was found in one case (1.08%). We neither identify atypical bacteria nor influenza virus. No association was found between the presence of viral or bacterial microorganisms and development of unfavorable outcomes (OR 1.63; 95% CI 0.45-5.82). Conclusion:A high frequency of respiratory pathogens was detected by molecular methods in patients with COVID-19 pneumonia but were not associated with unfavorable outcomes. No atypical agents or influenza virus were found. The high use antibiotics before admission is a concern. Our data suggest that the use of drug therapy against atypical bacteria and viruses would not be justified in patients hospitalized for COVID-19.

WSE is associated with better response to Erlotinib and improved progression-free survival in patients with NSCLC. Additional studies in epidermal growth factor receptor signaling pathway in WSE-associated NSCLC are warranted.

Objetivos: Comparar la tasa de mortalidad por COVID-19 a nivel nacional por regiones y departamentos desde marzo a septiembre del 2020. Métodos: Estudio cuantitativo, observacional, transversal, ecológico y retrospectivo. La data fue extraída del Sistema Nacional de Defunciones (SINADEF) en Microsoft Excel 2016 y se importó a Stata. Se obtuvo la mortalidad dividiendo el total de muertes sobre la población total de acuerdo al último censo. Se utilizó frecuencias y porcentajes, se realizó un análisis exploratorio ajustado con métodos de regresión robusta para evaluar la asociación entre mortalidad por departamento y regiones ajustado a edad y sexo. Se consideró significativo p< 0.05. Resultados: Se reportaron 32535 fallecidos, el 69,84% fueron varones y la mediana de edad fue 67. La mortalidad por mil habitantes, en la región Costa se calculó en 145 muertes (n=24276), seguido de Sierra con 51 (n=4434) y Selva con 63 (n=2545). Existieron diferencias significativas de mortalidad de acuerdo a la región, en la comparación de la costa con la sierra se halló un coeficiente beta de-96.28 (p <0,001 IC-123,76-68,77), mientras que en la comparación con la selva se determinó un coeficiente de-50,38 (p 0,01 IC 95%-91,47-9,29). No se encontró asociación significativa entre la mortalidad y la edad o el sexo de los fallecidos por departamento. Conclusión: La tasa de mortalidad por COVID-19 en Perú fue de 101 por 100000 habitantes, fue mayor en la costa que en la sierra y la selva independientemente de la proporción de varones, mujeres o la edad. Palabras clave: Mortalidad; Infecciones por coronavirus; COVID-19 (fuente: DeCS BIREME).

No abstract